Drug That Can Keep Breast Cancer at Bay for Longer
Byline: Jenny Hope Medical Correspondent
A BREAKTHROUGH drug gives women suffering an aggressive form of breast cancer an extra six months before the disease advances.
Women on a combination treatment of pertuzumab alongside the 'wonder' drug Herceptin lived on average for 18 months without their disease worsening, compared with 12 months for those not taking it.
Doctors are hailing the dual therapy as a 'quantum leap forward' that will change treatment in the same way Herceptin did five years ago.
A quarter of the 48,000 Britons diagnosed with breast cancer each year have the HER2 positive form, which is more aggressive.
When the …
The rest of this article is only available to active members of Questia
Sign up now for a free, 1-day trial and receive full access to:
- Questia's entire collection
- Automatic bibliography creation
- More helpful research tools like notes, citations, and highlights
- Ad-free environment
Already a member? Log in now.
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information:
Article title: Drug That Can Keep Breast Cancer at Bay for Longer.
Contributors: Not available.
Newspaper title: Daily Mail (London).
Publication date: December 8, 2011.
Page number: 4.
© 2007 Daily Mail.
COPYRIGHT 2011 Gale Group.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.
One moment ...
- Georgia
- Arial
- Times New Roman
- Verdana
- Courier/monospaced
Reset